This is the clinician view. It keeps every sentence of the plain guide and adds, for each section, the study design and citations of its sources. Every added sentence is cited and checked like the rest. Back to plain language.
Who is most at risk?
A simplified score uses four predictors. They are female sex, a history of motion sickness or of nausea after earlier surgery, not smoking, and the use of opioids after surgery. With none, one, two, three or four, the rates of postoperative nausea and vomiting were 10%, 21%, 39%, 61% and 79%.E2Good1
The authors suggested considering preventive medicine for people with at least two of the four.E2Good1
The evidence in this section (1 source)
| Source | Design | Grade | Citations (NIH iCite) |
|---|
| 1 Apfel CC, Anesthesiology, 1999 | Observational study | E2Good | 1,473 (RCR 57.76) |
|---|
What prevents it?
In a large factorial trial, ondansetron, dexamethasone and droperidol each reduced the risk by about 26%. Propofol reduced it by 19%, so total intravenous anesthesia worked about as well as one anti-nausea drug.E1Strong2
The same trial concluded that prevention is rarely warranted in low-risk patients. It concluded that one measure may help moderate-risk patients and several measures are for high-risk patients.E1Strong2
A Cochrane network meta-analysis found high-certainty evidence that five single drugs (aprepitant, ramosetron, granisetron, dexamethasone and ondansetron) reduce vomiting.E1Strong3
Combinations generally worked better than single drugs, and NK1 receptor antagonists such as aprepitant were the most effective class.E1Strong3
The fourth consensus guidelines cover identifying high-risk patients, lowering baseline risk, choosing prevention and rescue treatment, in adults and children.E2Good4
The evidence in this section (3 sources)
| Source | Design | Grade | Citations (NIH iCite) |
|---|
| 2 Apfel CC, N Engl J Med, 2004 | Randomized trial | E1Strong | 1,026 (RCR 37.63) |
|---|
| 3 Weibel S, Cochrane Database Syst Rev, 2020 | Meta-analysis | E1Strong | 229 (RCR 20.14) |
|---|
| 4 Gan TJ, Anesth Analg, 2020 | Consensus statement | E2Good | 950 (RCR 85.96) |
|---|
Questions you might bring to your anesthesia team
- I have had nausea after anesthesia before, or I get motion sickness: what is the prevention plan?
- Can the pain plan use fewer opioids?
- Would total intravenous anesthesia make sense for me?
Every claim in this guide was written from its sources and checked against them word for word. Its clinical review by Dr. Recio, a practicing nurse anesthesiologist (CRNA), is pending. This line changes when the review is done.
Nausea and vomiting – This very common side effect can occur within the first few hours or days after surgery and can be triggered by a number of factors, such as the medication, motion, and the type of surgery.
DIPRIVAN is an intravenous general anesthetic and sedation drug indicated for: (1) • Induction of General Anesthesia for Patients Greater than or Equal to 3 Years of Age • Maintenance of General Anesthesia for Patients Greater than or Equal to 2 Months of Age • Initiation and Maintenance of Monitored Anesthesia Care (MAC) Sedation in Adult Patients • Sedation for Adult Patients in Combination with Regional Anesthesia • Intensive Care Unit (ICU) Sedation of Intubated, Mechanically Ventilated Adult Patients
Guidelines are presented for safe practice in the use of intravenous drug infusions for general anaesthesia. When maintenance of general anaesthesia is by intravenous infusion, this is referred to as total intravenous anaesthesia.